Seattle Genetics and Bristol-Myers Squibb revealed provisional results from their study considering the potential combination of Adcetris (brentuximab vedotin) and Opdivo (nivolumab) in treating relapsed or refractory Hodgkin lymphoma.
The companies reported the results at the 59th American Society of Hematology (ASH) annual meeting and indicated optimism based on data from their Phase 1/2 study, according to a Bristol-Myers Squibb press release. Lead trial investigator Dr. Alex Herrera of Duarte, California’s City of Hope Medical Center said that interim results appear persuasive.
“The interim results … continue to look compelling, demonstrating both promising activity in addition to a manageable overall safety profile,” Herrera said in the release. “These data support further exploration of this novel, chemotherapy-free investigational regimen in HL patients.”
Data showed an 83 percent objective response rate and a 62 percent complete response rate — together with an acceptable safety profile — in pretransplant relapsed or refractory classical Hodgkin lymphoma patients, the release said. Additionally, data support a Phase 3 clinical trial.
Dr. Jonathan Drachman, chief medical officer and executive vice president for research and development at Seattle Genetics, concurred with Herrera’s assessment.
“We look forward to further evaluation of this innovative combination regimen in other disease settings, including the ongoing pivotal phase 3 CHECKMATE 812 study in patients with relapsed HL, in partnership with Bristol-Myers Squibb," Drachman said in the release.
